Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

medilink pharmaceuticals ltd - urea, hydrocortisone - cream - 10% w/w - 0000057136 - urea - 10 % w/w; 0000050237 - hydrocortisone - 1 % w/w - hydrocortisone

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - Σακχαρώδης διαβήτης τύπου 2 - Φάρμακα που χρησιμοποιούνται στον διαβήτη - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. θεραπεία τριπλού συνδυασμού) ως επιπρόσθετο στη δίαιτα και την άσκηση σε ασθενείς που δεν ελέγχονται επαρκώς με μέγιστη ανεκτή για αυτούς δόση μετφορμίνης και σουλφονυλουρίας. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

johnson & johnson ΕΛΛΑΣ ΚΑΤΑΝΑΛΩΤΙΚΑ ΠΡ.ΑΕΕ ΔΤ johnson & johnson ΕΛΛΑΣ consumer ae - others - ΣΑΠΩΝ ΓΙΑ ΤΟ ΤΡΙΧΩΤΟ ΤΗΣ ΚΕΦΑΛΗΣ (ΣΑΜΠΟΥΑΝ) - 5 mg/ml - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

healthcode ike, Δ.Τ. healthcode, ΕΛΛΑΔΑ 13 Μενεμένης, 17778 Ταύρος - echinacea purpurea; echinacea purpurea - chw.tab (ΜΑΣΩΜΕΝΟ ΔΙΣΚΙΟ) - (380+20)mg/tab - echinacea purpurea 380mg; echinacea purpurea 20mg

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

healthcode ike, Δ.Τ. healthcode, ΕΛΛΑΔΑ 13 Μενεμένης, 17778 Ταύρος - echinacea purpurea; echinacea purpurea - tab (ΔΙΣΚΙΟ) - (1140+60)mg/tab - echinacea purpurea 1.140mg; echinacea purpurea 60mg

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

healthcode ike, Δ.Τ. healthcode, ΕΛΛΑΔΑ 13 Μενεμένης, 17778 Ταύρος - echinacea purpurea; echinacea purpurea - or.so.d (ΠΟΣΙΜΕΣ ΣΤΑΓΟΝΕΣ, ΔΙΑΛΥΜΑ) - (860+45)mg/ml - echinacea purpurea 860mg; echinacea purpurea 45mg

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

healthcode ike, Δ.Τ. healthcode, ΕΛΛΑΔΑ 13 Μενεμένης, 17778 Ταύρος - echinacea purpurea; echinacea purpurea; salvia officinalis - mouth spr (ΣΤΟΜΑΤΙΚΟ ΕΚΝΕΦΩΜΑ) - (863.3+45.5+430)mg/ml - echinacea purpurea 863,3mg; echinacea purpurea 45,5mg; salvia officinalis 430mg

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

biologische heilmittel heel gmbh, germany dr. reckeweg stra. 2-4, 76532 baden-baden +49 7221 501-00 - achillea millefolium; aconitum napellus; arnica montana; atropa belladona; bellis perennis; calendula officinalis; echinacea; echinacea purpurea; hamamelis virginiana; hepar sulfuris; hypericum perforatum; matricaria recutita; mercurius solubilis hahnemanni; symphytum officinale - ointment (ΑΛΟΙΦΗ) - achillea millefolium 0,09g; aconitum napellus 0,05g; arnica montana 1,5g; atropa belladona 0,05g; bellis perennis 0,1g; calendula officinalis 0,45g; echinacea 0,15g; echinacea purpurea 0,15g; hamamelis virginiana 0,45g; hepar sulfuris 0,025g; hypericum perforatum 0,09g; matricaria recutita 0,15g; mercurius solubilis hahnemanni 0,04g; symphytum officinale 0,1g - not yet assigned

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - Σακχαρώδης διαβήτης τύπου 2 - Φάρμακα που χρησιμοποιούνται στον διαβήτη - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. θεραπεία τριπλού συνδυασμού) ως επιπρόσθετο στη δίαιτα και την άσκηση σε ασθενείς που δεν ελέγχονται επαρκώς με μέγιστη ανεκτή για αυτούς δόση μετφορμίνης και σουλφονυλουρίας. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - Σακχαρώδης διαβήτης τύπου 2 - Φάρμακα που χρησιμοποιούνται στον διαβήτη - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. θεραπεία τριπλού συνδυασμού) ως επιπρόσθετο στη δίαιτα και την άσκηση σε ασθενείς που δεν ελέγχονται επαρκώς με μέγιστη ανεκτή για αυτούς δόση μετφορμίνης και σουλφονυλουρίας. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.